Tag: Guerbet
ACR Committee on Drugs and Contrast Media classifies Elucirem injection a...
Guerbet has announced in a press release that based on the most recent scientific and clinical evidence, the American College of Radiology (ACR) Committee...
Guerbet announces first patient dosing with Elucirem for contrast-enhanced MRI
Guerbet has shared in a press release that it has commercially launched Elucirem (gadopiclenol) and the first patient has received a dosing. This is...
Guerbet releases first batch of Elucirem for contrast-enhanced MRI
Guerbet has announced the first production batch has been manufactured and released for Elucirem (gadopiclenol) injection following US Food and Drug Administration (FDA) approval...
INSPIRE initiative seeks to standardise cTACE across the world
Thierry De Baère (Gustave Roussy; Villejuif, France) talks to Interventional News about the rationale behind setting up the Initiative on Superselective Conventional Transarterial Chemoembolization (INSPIRE), which...
Guerbet announces US Food and Drug Administration approval of Elucirem
Guerbet announced that the US Food and Drug Administration (FDA), after priority review, has approved Elucirem (Gadopiclenol), a new macrocyclic gadolinium-based contrast agent (GBCA)...
Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and...
Guerbet announces it will more than double its line of microcatheters and launch a new line of guidewires, resulting in a broad range of...
Guerbet launches new injection technical service
Contrast developer Guerbet has launched OptiProtect 3S, a new range of technical services for its contrast injectors.
OptiProtect 3S offers technical service and support for all Guerbet...
UK approves Lipiodol Ultra Fluid for hysterosalpingography in women undergoing infertility...
Guerbet has been granted approval for an indication extension in the UK, where Lipiodol Ultra Fluid is the only oil-based contrast medium indicated for...
Early experience with the SeQure® microcatheter reduces risks of non-target embolization...
This advertorial is sponsored by Guerbet. SeQure®
As the leader of an investigator-initiated, Phase 2 study evaluating the safety and efficacy of the SeQure® microcatheter...
Lipidol Ultra-Fluid recevies approval for use in cTACE by China NMPA
Guerbet has announced the approval of an additional indication for Lipiodol Ultra-Fluid by the China NMPA (National Medical Products Administration) for use in transarterial...
Vectorio approved in Canada, an innovative medical device for interventional oncology...
Guerbet has announced the registration of Vectorio, a kit for imaging hepatocellular carcinoma (HCC), in Canada.
The kit consists of a set of Lipiodol-resistant medical...
Coalition of cTACE and immunotherapy: Expanding the horizons of interventional oncology
This article is sponsored by Guerbet. immunotherapy
Preliminary evidence suggests that combining conventional transarterial chemoembolization (cTACE) with immunotherapy could be beneficial to patients with unresectable...
ET 2019: New microcatheters could help reduce the “everyday challenge” of...
Irene Bargellini (Pisa, Italy) tells BLearning IR at the first Embolotherapy conference (ET; 26–29 June, Valencia, Spain) that non-target embolization is a frequently under-diagnosed,...
New indication approved for Guerbet’s Lipiodol Ultra Fluid
A new indication for Lipiodol Ultra Fluid (Guerbet) has been approved in Switzerland and in India for chemoembolization (cTACE) of tumours in adults with...
Guerbet receives CE mark approval for SeQure and DraKon microcatheters for...
SeQure and DraKon (Guerbet), two novel microcatheters for peripheral embolization procedures, are set for commercial launch in Europe. The devices have received the CE...
Guerbet announces appointment of Leeann Essai as North American head of...
Leeann Essai has joined Guerbet’s executive team as North American head of marketing.
In this role, Essai will report to Massimo Carrara, Guerbet vice president...
Guerbet announces commercial partnership with Imalogix
Guerbet has announced a commercial partnership with Imalogix, a company focusing on artificial intelligence process and workflow solutions. The commercial partnership combines Guerbet's diagnostic...
Vectorio®: Efficacy and safety for improved cTACE mixing and delivery
This educational supplement, sponsored by Guerbet, is intended for readers in the EU only. Guerbet obtained the CE mark for its conventional transarterial chemoembolization...
Guerbet launches two new microcatheters for use in embolization procedures
Guerbet has announced the upcoming launch of SeQure and DraKon, two novel microcatheters for tumour and vascular aneurysm embolization procedures. The company introduced the...
Guerbet acquires Occlugel and new microsphere technology for initial €3 million...
Guerbet has announced that it has signed an agreement to acquire a laboratory-stage technology developed by Occlugel, a French company specialised in the research...
Guerbet announces Lausanne partnership to evaluate immunogenic potential of cTACE
Guerbet has announced a partnership with the Department of Radiodiagnosis and Interventional Radiology of Lausanne's University Hospital (CHUV) and the Lausanne Center for Experimental...
Guerbet acquires IR microcatheter maker Accurate Medical
Guerbet has announced that it has entered into an agreement under which it will acquire Israeli company Accurate Medical, which specialises in the development...
Guerbet announces CE mark for Vectorio mixing and injection system for...
Guerbet has announced obtaining the CE mark for its conventional transarterial chemoembolization (cTACE) mixing and injection system, Vectorio.
Designed in collaboration with interventional radiologists worldwide,...
German Federal Institute for Drugs and Medical Devices approves new indication...
Guerbet has announced that the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM; The German Federal Institute for Drugs and Medical Devices) has now approved Lipiodol...
Thailand FDA approves new indication for Guerbet’s Lipiodol Ultra-Fluide
Guerbet has announced that the Thailand FDA has given approval of a new indication for Lipiodol Ultra-Fluide for selective hepatic intra-arterial injection for visualisation,...
Guerbet expands distribution partnership in Canada with Methapharm
Guerbet has announced that as of 1 February 2017, Methapharm will promote and distribute all Guerbet products in Canada.
"As a result of our excellent...
